在COVID-19简单试验的第3期重度和中度试验中没有观察到雷梅西维尔耐药性
Charlotte Hedskog1, Christoph D Spinner2, Ulrike Protzer3,4,5
1Gilead Sciences, Inc., Foster City, CA 94404, USA.
Viruses
|April 27, 2024
概括
针对COVID-19的雷姆迪西维尔 (RDV) 治疗没有显著的病毒抗性. 临床试验的分析证实了RDV.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 雷姆迪西维尔 (Remdesivir,简称RDV) 是一种已批准用于治疗COVID-19的抗病毒药物.
- 临床试验已经证明了RDV在住院患者中的有效性.
研究的目的:
- 在住院COVID-19患者中分析SARS-CoV-2对Remdesivir (RDV) 的耐药性.
- 评估影响RDV易感性的病毒突变的出现.
主要方法:
- 从第三阶段简单的临床研究中对病毒学样本进行了回顾性分析.
- 测序和病毒载荷数据从研究地点的子集收集.
- 分析侧重于具有基线和基线后测序数据的参与者.
主要成果:
- 在严重的COVID-19研究中,21%的参与者观察到出现的NSP12替代物.
- 在5种已识别的替代物中,有4种 (T76I,A526V,A554V,C697F) 没有显著改变RDV易感性.
- 替代品E665K不能被表型化.
结论:
- 没有发现相关的Remdesivir (RDV) 耐药性的证据.
- 这些发现支持RDV在COVID-19治疗中的已确定的疗效和高耐药性障碍.
相关概念视频
Retrovirus Life Cycles
45.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.9K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K


